ReNerve (ASX: RNV) received an additional AU$139,537 in research and development tax incentives following an assessment of the company's overseas research activities, bringing its total refund to AU$516,606, according to a Friday filing with the Australian bourse.
The company said it is working and developing products aimed to provide a complete range of products for peripheral nerve repair and replacement.
The company's shares were down almost 4% in recent Friday trade, earlier hitting an all-time low.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.